Fig. 2
From: Antigen-Specific IgG Antibodies in Stage IV Long-Time Survival Breast Cancer Patients
ELISA reactivity of the phage displayed SQRIPARIHHFPTSI peptide with patients and control sera. (A) The reactivity of 16 patients with breast cancer with stage IV (◇) and 35 normal individuals (◆) toward the phage-displayed SQRIPARIHHFPTSI peptide was tested by ELISA. The absorbency of each serum was obtained by subtracting its absorbency to a phage displaying a random peptide as described in Materials and Methods. (B) Inhibition of the serum antibody to bind the phage-displayed SQRIPARIHHFPTSI peptide by the phage itself or by a phage displaying an irrelevant peptide (Wt phage). (C) Inhibition with synthetic peptides.